SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CTMX

CytomX Therapeutics, Inc. (NASDAQ:CTMX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.03-$0.02 (-0.98%)
 
Market cap
$443M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 8, 2015
Website
Market Cap$442.55M-47.7%
Revenue (ttm)$14.03M-87.7%
Net Income-$85.42M-404.9%
EPS-$0.45-207.8%
Shares Out218.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,867,850
Open$2.02
Previous Close$2.05
Day's Range$1.99 - $2.16
52-Week Range$1.87 - $8.21
Beta2.24
AnalystsBuy
Price Target$10.71(+427.59%)
Earnings DateFeb 24, 2027

About CTMX

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Address
151 Oyster Point Boulevard, South San Francisco, CA, 94080, US
Market Cap
443 million
Employees
69
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.16M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $11.50 (+492.8%)

2 firms rating CTMX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From CTMX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.98%
5 Days
+0.50%
1 Month
-15.42%
6 Months
-46.01%
1 Year
-47.68%

$CTMX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CTMX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CTMX's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CTMX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CTMX Revenue by Segment

$14.91MTotal
Internal costs$9.45M63.39%
Varseta-M (EpCAM)$3.79M25.41%
CX-801 (IFNAlpha2b)$949.00K6.36%
Other income$294.00K1.97%
Other Wholly Owned and Partnered Programs$239.00K1.60%
CX-904 (EGFRxCD3)$188.00K1.26%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CTMX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CTMX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CTMX

VTIVanguard Morningstar Total Stock Market ETF$11.49M
XBIState Street SPDR S&P Biotech ETF$10.67M
IWMiShares Russell 2000 ETF$10.04M
VXFVanguard Extended Market ETF$5.44M
IBBiShares Biotechnology ETF$3.04M
VTWOVanguard Russell 2000 ETF$2.60M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CTMX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: CytomX achieved milestone payments from strategic Regeneron collaboration, demonstrating validation of core technology platform.

Recent Insider Activity

Buys
0
Sells
7
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.52%
QQQSInvesco NASDAQ Future Gen 200 ETF0.36%
IDNAiShares Genomics Immunology and Healthcare ETF0.32%
CANCTema Oncology ETF0.25%
XBIState Street SPDR S&P Biotech ETF0.10%
IWCiShares Micro-Cap ETF0.10%
FFSMFidelity Fundamental Small-Mid Cap ETF0.06%
FSMOFidelity Fundamental Small-Mid Cap ETF0.06%
STSBiShares Factors US Small Blend Style ETF0.06%
IBBQInvesco Nasdaq Biotechnology ETF0.03%
IBBiShares Biotechnology ETF0.03%
PWSPacer WealthShield ETF0.02%

Weight is the stock’s share of each fund’s holdings.